Health and Healthcare

Atara Biotherapeutics : ATRA

ATRA

Stock Data

$10.07

$0.40 (4.14%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.

All Atara Biotherapeutics Articles

2 Articles

Jon C. Ogg | Sep 15, 2020 at 1:01 PM EDT

Beyond Mesothelioma, Multiple Sclerosis Could Help Atara’s Stock Soar Exponentially

On Tuesday, Canaccord Genuity reiterated its rating on Atara Biotherapeutics and raised its wildly bullish target price even higher.

Jon C. Ogg | May 26, 2020 at 12:21 PM EDT

Should Atara Bio’s Stock Volatility Consider Any Valuation at All on Multiple Sclerosis?

Atara Biotherapeutics finds itself caught between a rock and a hard place after Friday's drug study news concerning its treatment…